ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global
Investment Conference on September 12, 2011 - MarketWatch





Bulletin

Get news bulletins by email &raquo; U.S. stocks sharply lower as NYSE
invokes &#39;Rule 48&#39; for Tuesday&#39;s open







Sign in

Become a MarketWatch member today


* Front Page
* News Viewer
* Commentary
* Markets
* Investing
* Personal Finance
* Community
* Games














press release

Sept. 6, 2011, 9:00 a.m. EDT


ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global
Investment Conference on September 12, 2011




















SAN DIEGO, Sep 06, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. ,
a biopharmaceutical company utilizing innovative technology to fuel drug
discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will present at the
Rodman & Renshaw Annual Global Investment Conference on Monday, September
12, 2011, at 4:30 p.m. Eastern Time at The Waldorf=Astoria Hotel in New
York City.

A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com , under the investors section and
an archived recording will be available on the website through September
26, 2011.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA has a portfolio of four product
candidates including pimavanserin, which is in Phase III development as a
potential first-in-class treatment for Parkinson's disease psychosis.
ACADIA also has a product candidate in Phase II for chronic pain and a
product candidate in Phase I for glaucoma, both in collaboration with
Allergan, Inc. as well as a product candidate in IND-track development
for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. All
of the product candidates in ACADIA's pipeline emanate from discoveries
made using its proprietary drug discovery platform. ACADIA maintains a
website at www.acadia-pharm.com to which ACADIA regularly posts copies of
its press releases as well as additional information and through which
interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA's
drug discovery and development programs either alone or with a partner,
including clinical trials, and the benefits to be derived from ACADIA's
product candidates, in each case including pimavanserin. These statements
are only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or results may
differ materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and collaborations with
others, and the fact that past results of clinical trials may not be
indicative of future trial results. For a discussion of these and other
factors, please refer to ACADIA's annual report on Form 10-K for the year
ended December 31, 2010 as well as other subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All forward-looking
statements are qualified in their entirety by this cautionary statement
and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except
as required by law.

SOURCE: ACADIA Pharmaceuticals Inc.




        
        ACADIA Pharmaceuticals Inc. 
        Thomas H. Aasen, Executive Vice President, 
        Chief Financial Officer and Chief Business Officer 
        (858) 558-2871
        




Copyright Business Wire 2011


/quotes/zigman/85163/quotes/nls/acad





Add ACAD to portfolio ACAD



ACADIA Pharmaceuticals Inc.



$ 1.29

-0.02 -1.15%




Volume: 30,955

Sept. 6, 2011 9:38a










































Most Popular


1. 




2. 




3. 




4. 




5. 







Find a Broker


Ã‚Â»

















Featured Stories


* U.S. stock futures drop; Swiss franc slumps


* 
* Why the young jobless will ruin your portfolio

  Without jobs or accumulated wealth todayÃ¢Â€Â™s young Americans
  wonÃ¢Â€Â™t be able to retire, and those retiring soon...


* What to buy and what to avoid for the rest of 2011

  After this summerÃ¢Â€Â™s volatile sell-off, lower earnings expectations
  are already priced into stocks across...


* Dow headed below 10,000 as cyclical bear begins

  Technical pattern on the Dow Jones Industrial Average suggests the
  stock market has unfinished business to...














* WSJ
  o WSJ

* MarketWatch
  o MarketWatch
  o Facebook
  o Twitter





* Barron's
  o Barron's

* SmartMoney
  o SmartMoney

* AllThingsDigital
  o AllThingsDigital

* FINS
  o FINS

* More
  o BigCharts
  o Virtual Stock Exchange
  o Financial News
  o WSJ Asia
    - WSJ India
    - 
    - 

  o WSJ Europe
  o WSJ Americas
    - en Espa&ntilde;ol
    - em Portugu&ecirc;s

  o WSJ Radio
  o WSJ Wine





SEARCH








9:40 AM EDT

September 6, 2011


/marketstate/country/us
New York

Open


/marketstate/country/uk
London

Open


/marketstate/country/jp
Tokyo

Closed






/marketstate/country/us



/marketstate/country/uk



/marketstate/country/jp













View All


Latest News


1. /news/latest 9:38a

   Newmont Mining up 2%, best on S&amp;P 500

2. 9:37a

   BREAKING

   U.S. stocks open sharply lower; Rule 48 invoked

3. 9:35a

   Marathon Oil shares drop 6.7% in early trade

4. 9:34a

   Harley-Davidson shares fall 7.8%, worst on S&amp;P 500

5. 9:32a

   BREAKING

   U.S. stocks open sharply lower; Rule 48 invoked

6. 9:29a

   CFPB nominee says he doesn&#39;t favor lawsuits

7. 9:23a

   Swiss escalation of currency wars to boost gold

8. 9:11a

   When using cash is better than credit

9. 9:11a

   Coming up: ISM services for August

10. 9:09a

    Treasurys up; 10-year yields hit record low

11. 9:00a

    What to buy and what to avoid for the rest of 2011

12. 8:59a

    Private-equity group Carlyle files for IPO

13. 8:55a

    U.S. stock futures drop; Swiss franc slumps

14. 8:51a

    European markets turn lower amid sovereign fears

15. 8:49a

    Europe, SNB in the spotlight

16. 8:48a

    PepsiCo, NFL renew &quot;multi-year&quot; sponsorship deal

17. 8:44a

    Why the young jobless will ruin your portfolio

18. 8:44a

    TuesdayÃ¢Â€Â™s biggest gaining &amp; declining stocks

19. 8:43a

    Italy budget backtrack stirs market worries

20. 8:34a

    Wells Fargo starts Dunkin&#39; at market perform

21. Loading more headlines...





dow


/quotes/zigman/627449/delayed
10,978.09


-262.17

-2.33%








nasdaq


/quotes/zigman/123127
2,427.62


-52.71

-2.13%








s&amp;p 500


/quotes/zigman/3870025
1,145.13


-28.84

-2.46%














Kiosk


* 1309316400000

  1309377600000



  Commodities Corner




  Myra P. Saefong
  Benching a benchmark Ã‚Â 
  West Texas Intermediate, the oil index long used to project U.S.
  motor-fuel price trends, no longer is accurate benchmark. Here's what's
  replaced it.


  /conga/kiosk/commentary3.html 166051



* 1309982400000

  1310072100000



  Tech Investor




  John Shinal
  Learning the lesson of tech jobs
  There are larger implications for the U.S. economy to be found in the
  hiring trends in the domestic tech sector, and in India.


  /conga/kiosk/commentary.html 166049



* 1309370400000

  1309428000000



  Second Opinion




  John C. Dvorak
  Dell can dominate PC world
  This is the perfect opportunity to wrest control of the U.S. PC
  business from Apple and H-P, and take over in China as well. All Dell
  has to do is execute.


  /conga/kiosk/wildcard4.html 166054



* 1241971200000

  1242619200000



  Weekend Investor




  The fine art of investing
  As an asset class, fine art is a proven long-term store of wealth. The
  current marketÃ‚Â  woes just add to art's allure.


  /conga/kiosk/investing.html 166124



* 1308830400000

  1308901200000



  Asia




  Rich tastes get pricier
  The cost of living the luxury life in Asia soared in dollar terms over
  the past year, according to a lifestyle index. What's behind the higher
  luxury prices?


  /conga/kiosk/wildcard2.html 165868



* 1303590000000

  1303749600000



  Car Review




  2012 VW Beetle Turbo
  It may resemble the "New Beetle,"Ã‚Â  but Volkswagen's 2012 offering is
  a better bug, writes Ron Amadon.
  Ã¢Â€Â¢ More car reviews from Ron Amadon


  165998



* 1247536800000

  1247587200000



  The Economy


  Ã‚Â 

  A moribund jobs market
  Data showed the U.S. economy still struggling to create jobs with
  payrolls creation flat, hourly earnings falling, and grim
  African-American jobless rates.


  /conga/kiosk/economy-politics.html 165896













MarketWatch.com

* Site Index
* Topics
* Help
* Feedback
* Newsroom Roster
* Media Archive
* Premium Products
* Mobile

* Company Info
* Code of Conduct
* Corrections
* Advertising Media Kit
* Advertise Locally
* License our Content
* Broker Center

* MarketWatch on Facebook
* 
* MarketWatch on Twitter
* 
* RSS
* Podcasts



* WSJ.com
* Barron's Online
* BigCharts
* Virtual Stock Exchange
* All Things Digital

* MarketWatch Community
* Financial News Online
* WSJ.com Small Business
* FINS: Finance, IT jobs, Sales jobs









Copyright © 2011 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy.



Intraday Data provided by SIX Telekurs and subject to terms of use.
Historical and current end-of-day data provided by SIX Telekurs. Intraday
data delayed per exchange requirements. Dow Jones Indexes (SM) from Dow
Jones & Company, Inc. All quotes are in local exchange time. Real time
last sale data provided by NASDAQ. More information on NASDAQ traded
symbols and their current financial status. Intraday data delayed 15
minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones
IndexesSM from Dow Jones & Company, Inc. SEHK intraday data is provided
by SIX Telekurs and is at least 60-minutes delayed. All quotes are in
local exchange time.







* MarketsMarkets







  Data is loading...




* QuotesQuotes







  Data is loading...




* My PortfolioMy Portfolio







  Data is loading...




* My AlertsMy Alerts







  Data is loading...




* CommunityCommunity




  HOT PICKS MY PICKS MY GROUPS




  Data is loading...





ALERT:




MarketWatch Top Stories
Link to MarketWatch's Slice. 15







Email address or display name


Password




Remember me

Forgot password?






The action you requested requires a MarketWatch Community display name.




Sign In


Email address or display name


Password




Remember me

Forgot password?



Community

Get your FREE membership now Ã‚Â»

MarketWatch Community is a free service that lets you discover, organize
and share MarketWatch stories with other readers.

Learn More Ã‚Â»





The action you requested is only available to MarketWatch members.
Please sign in or register.




Sign In


Email address or display name


Password




Remember me

Forgot password?




Register

Don't have a MarketWatch account?

Get your FREE membership now Ã‚Â»


By registering, you are agreeing to MarketWatch's Terms of Service and to
receiving periodic news and special offers via email about MarketWatch
enhancements, products and services.



